EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.335
https://www.valueinhealthjournal.com/article/S1098-3015(23)03465-4/fulltext
Title :
EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03465-4&doi=10.1016/j.jval.2023.09.335
First page :
Section Title :
Open access? :
No
Section Order :
12357